Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
Duality Biologics, a developer of novel modality drugs operating in the United States and China,...
NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines
The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...
NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use
The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
EOC Pharma, a biotech company operating in the US and China, has announced that its...
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...
Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...
China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...
Zhongchao Partners with Natco Pharma to Distribute Drugs in China
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...
By-Health to Establish Nutrition Research Center with Shanghai Institute
China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...
Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...
Everest Medicines Outlines Strategic Plans for Expansion and Growth
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...